Wall Street analysts forecast that Ecolab (ECL) will report quarterly earnings of $1.82 per share in its upcoming release, pointing to a year-over-year increase of 18.2%. It is anticipated that revenues will amount to $4.02 billion, exhibiting an increase of 1.7% compared to the year-ago quarter.

The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

That said, let's delve into the average estimates of some Ecolab metrics that Wall Street analysts commonly model and monitor.

The combined assessment of analysts suggests that 'Sales- Global Healthcare and Life Sciences (Fixed currency)' will likely reach $330.73 million. The estimate suggests a change of -17.5% year over year.

Analysts expect 'Sales- Global Industrial (Public Currency rates)' to come in at $2.00 billion. The estimate indicates a change of +8.5% from the prior-year quarter.

Based on the collective assessment of analysts, 'Sales- Global Institutional & Specialty (Fixed currency)' should arrive at $1.40 billion. The estimate suggests a change of +6.9% year over year.

It is projected by analysts that the 'Sales- Global Institutional & Specialty (Public Currency rates)' will reach $1.39 billion. The estimate indicates a change of +5.8% from the prior-year quarter.

The consensus estimate for 'Sales- Global Industrial (Fixed currency)' stands at $2.00 billion. The estimate indicates a year-over-year change of +9.6%.

The average prediction of analysts places 'Sales- Global Healthcare & Life Sciences (Public Currency rates)' at $363.51 million. The estimate indicates a year-over-year change of -10.5%.

According to the collective judgment of analysts, 'Operating Income- Global Healthcare and Life Sciences (Fixed currency)' should come in at $27.11 million. Compared to the current estimate, the company reported $44 million in the same quarter of the previous year.